CR10870A - Derivados de purina 7-sustituidos para inmunosupresion - Google Patents
Derivados de purina 7-sustituidos para inmunosupresionInfo
- Publication number
- CR10870A CR10870A CR10870A CR10870A CR10870A CR 10870 A CR10870 A CR 10870A CR 10870 A CR10870 A CR 10870A CR 10870 A CR10870 A CR 10870A CR 10870 A CR10870 A CR 10870A
- Authority
- CR
- Costa Rica
- Prior art keywords
- immunosuppression
- replaced
- purine derivatives
- derivatives
- moderate
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Pain & Pain Management (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Rheumatology (AREA)
- Ophthalmology & Optometry (AREA)
- Transplantation (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
La presente invencion provee nuevos derivados de purinona y derivados relacionados utiles para la prevencion y tratamiento de enfermedades autoinmunes, enfermedad inflamatoria, enfermedad moderada por celula cebada y rechazo de trasplante. Los compuestos de la formula general (III).
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/US2006/061004 WO2008060301A1 (en) | 2006-11-16 | 2006-11-16 | 7-substituted purine derivatives for immunosuppression |
Publications (1)
Publication Number | Publication Date |
---|---|
CR10870A true CR10870A (es) | 2009-12-01 |
Family
ID=38578618
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CR10870A CR10870A (es) | 2006-11-16 | 2009-06-16 | Derivados de purina 7-sustituidos para inmunosupresion |
Country Status (11)
Country | Link |
---|---|
EP (1) | EP2099800A1 (es) |
JP (1) | JP2010510211A (es) |
KR (1) | KR20100014271A (es) |
CN (1) | CN101595110A (es) |
AU (1) | AU2006350748A1 (es) |
BR (1) | BRPI0622030A2 (es) |
CA (1) | CA2669686A1 (es) |
CR (1) | CR10870A (es) |
IL (1) | IL198761A0 (es) |
MX (1) | MX2009005194A (es) |
WO (1) | WO2008060301A1 (es) |
Families Citing this family (37)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7884109B2 (en) * | 2005-04-05 | 2011-02-08 | Wyeth Llc | Purine and imidazopyridine derivatives for immunosuppression |
US7989459B2 (en) * | 2006-02-17 | 2011-08-02 | Pharmacopeia, Llc | Purinones and 1H-imidazopyridinones as PKC-theta inhibitors |
WO2010103130A2 (en) | 2009-03-13 | 2010-09-16 | Katholieke Universiteit Leuven, K.U.Leuven R&D | Novel bicyclic heterocycles |
CA2758614A1 (en) | 2009-04-14 | 2010-10-21 | Cellzome Limited | Fluoro substituted pyrimidine compounds as jak3 inhibitors |
WO2011029807A1 (en) | 2009-09-11 | 2011-03-17 | Cellzome Limited | Ortho substituted pyrimidine compounds as jak inhibitors |
MX2012004020A (es) | 2009-10-20 | 2012-05-08 | Cellzome Ltd | Analogos de heterociclilo pirazolopirimidina como inhibidores de jak. |
EP2493895B1 (en) | 2009-10-29 | 2017-04-26 | Vectura Limited | N-containing heteroaryl derivatives as jak3 kinase inhibitors |
CA2797772A1 (en) | 2010-04-30 | 2011-11-03 | Cellzome Limited | Pyrazole compounds as jak inhibitors |
GB201012889D0 (en) | 2010-08-02 | 2010-09-15 | Univ Leuven Kath | Antiviral activity of novel bicyclic heterocycles |
DK2578585T3 (en) | 2010-05-31 | 2016-11-14 | Ono Pharmaceutical Co | PURINONDERIVAT AS BTK kinase inhibitor |
US20130165426A1 (en) * | 2010-07-06 | 2013-06-27 | Université de Montréal | Imidazopyridine, imidazopyrimidine and imidazopyrazine derivatives as melanocortin-4 receptor modulators |
US9040545B2 (en) | 2010-08-20 | 2015-05-26 | Cellzome Limited | Heterocyclyl pyrazolopyrimidine analogues as selective JAK inhibitors |
KR101227388B1 (ko) * | 2010-09-09 | 2013-01-30 | 주식회사 만도 | 3웨이 형식의 저압 배기가스 재순환 밸브 구조 |
GB201015411D0 (en) | 2010-09-15 | 2010-10-27 | Univ Leuven Kath | Anti-cancer activity of novel bicyclic heterocycles |
US9018395B2 (en) | 2011-01-27 | 2015-04-28 | Université de Montréal | Pyrazolopyridine and pyrazolopyrimidine derivatives as melanocortin-4 receptor modulators |
WO2012143320A1 (en) | 2011-04-18 | 2012-10-26 | Cellzome Limited | (7h-pyrrolo[2,3-d]pyrimidin-2-yl)amine compounds as jak3 inhibitors |
EP2736901A1 (en) | 2011-07-28 | 2014-06-04 | Cellzome Limited | Heterocyclyl pyrimidine analogues as jak inhibitors |
WO2013017479A1 (en) | 2011-07-29 | 2013-02-07 | Cellzome Limited | Pyrazolo[4,3-c]pyridine derivatives as jak inhibitors |
WO2013017480A1 (en) | 2011-07-29 | 2013-02-07 | Cellzome Limited | Pyrazolo[4,3-c]pyridine derivatives as jak inhibitors |
WO2013025628A1 (en) | 2011-08-15 | 2013-02-21 | Ligand Pharmaceuticals Incorporated | Janus kinase inhibitor compounds and methods |
CA2849340A1 (en) | 2011-09-20 | 2013-03-28 | Cellzome Limited | Pyrazolo[4,3-c]pyridine derivatives as kinase inhibitors |
PL2786996T3 (pl) | 2011-11-29 | 2017-01-31 | Ono Pharmaceutical Co., Ltd. | Chlorowodorowa pochodna purynonu |
CN104169272A (zh) | 2011-12-23 | 2014-11-26 | 赛尔佐姆有限公司 | 作为激酶抑制剂的嘧啶-2,4-二胺衍生物 |
US8501724B1 (en) * | 2012-01-31 | 2013-08-06 | Pharmacyclics, Inc. | Purinone compounds as kinase inhibitors |
WO2014013014A1 (en) | 2012-07-18 | 2014-01-23 | Fundació Privada Centre De Regulació Genòmica (Crg) | Jak inhibitors for activation of epidermal stem cell populations |
WO2015089218A1 (en) | 2013-12-10 | 2015-06-18 | David Wustrow | Monocyclic pyrimidine/pyridine compounds as inhibitors of p97 complex |
CN106458996B (zh) | 2014-01-20 | 2020-11-03 | 克里弗生物科学公司 | 作为p97复合物的抑制剂的稠合嘧啶 |
ES2806506T3 (es) | 2014-03-25 | 2021-02-17 | Ono Pharmaceutical Co | Agente profiláctico y/o agente terapéutico para el linfoma difuso de células B grandes |
EP3281943B1 (en) | 2015-04-09 | 2023-06-28 | ONO Pharmaceutical Co., Ltd. | Process for producing purinone derivative |
MX2021001186A (es) | 2015-11-20 | 2022-10-11 | Forma Therapeutics Inc | Purinonas como inhibidores de proteasa especifica de ubiquitina 1. |
WO2018041989A1 (en) | 2016-09-02 | 2018-03-08 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for diagnosing and treating refractory celiac disease type 2 |
WO2018212162A1 (ja) * | 2017-05-17 | 2018-11-22 | 株式会社トクヤマ | ジアミノベンゼン化合物の製造方法 |
WO2020201362A2 (en) | 2019-04-02 | 2020-10-08 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods of predicting and preventing cancer in patients having premalignant lesions |
US20220202820A1 (en) | 2019-04-16 | 2022-06-30 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Use of jak inhibitors for the treatment of painful conditions involving nav1.7 channels |
KR102516260B1 (ko) * | 2020-07-10 | 2023-03-31 | 울산과학기술원 | Trap1 선택적 억제제로서의 화합물 및 이를 포함하는 암 예방 또는 치료용 조성물 |
KR102579424B1 (ko) * | 2021-02-19 | 2023-09-18 | 울산과학기술원 | 미토콘드리아 내부 축적이 증가된 trap1 선택적 억제제로서의 화합물 및 이의 용도 |
WO2023222565A1 (en) | 2022-05-16 | 2023-11-23 | Institut National de la Santé et de la Recherche Médicale | Methods for assessing the exhaustion of hematopoietic stems cells induced by chronic inflammation |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PT1704145E (pt) * | 2004-01-12 | 2012-09-04 | Ym Biosciences Australia Pty | Inibidores de quinase seletivos |
AR054416A1 (es) * | 2004-12-22 | 2007-06-27 | Incyte Corp | Pirrolo [2,3-b]piridin-4-il-aminas y pirrolo [2,3-b]pirimidin-4-il-aminas como inhibidores de las quinasas janus. composiciones farmaceuticas. |
CN101142218B (zh) * | 2005-02-03 | 2013-02-06 | 沃泰克斯药物股份有限公司 | 可用作蛋白激酶抑制剂的吡咯并嘧啶 |
EP1874772A1 (en) * | 2005-04-05 | 2008-01-09 | Pharmacopeia, Inc. | Purine and imidazopyridine derivatives for immunosuppression |
-
2006
- 2006-11-16 AU AU2006350748A patent/AU2006350748A1/en not_active Abandoned
- 2006-11-16 JP JP2009537135A patent/JP2010510211A/ja not_active Withdrawn
- 2006-11-16 CA CA002669686A patent/CA2669686A1/en not_active Abandoned
- 2006-11-16 EP EP06850161A patent/EP2099800A1/en not_active Withdrawn
- 2006-11-16 BR BRPI0622030-4A patent/BRPI0622030A2/pt not_active IP Right Cessation
- 2006-11-16 MX MX2009005194A patent/MX2009005194A/es not_active Application Discontinuation
- 2006-11-16 KR KR1020097012508A patent/KR20100014271A/ko not_active Application Discontinuation
- 2006-11-16 WO PCT/US2006/061004 patent/WO2008060301A1/en active Application Filing
- 2006-11-16 CN CNA2006800567754A patent/CN101595110A/zh active Pending
-
2009
- 2009-05-14 IL IL198761A patent/IL198761A0/en unknown
- 2009-06-16 CR CR10870A patent/CR10870A/es not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
EP2099800A1 (en) | 2009-09-16 |
AU2006350748A2 (en) | 2009-08-06 |
BRPI0622030A2 (pt) | 2014-04-22 |
IL198761A0 (en) | 2010-02-17 |
CA2669686A1 (en) | 2008-05-22 |
JP2010510211A (ja) | 2010-04-02 |
KR20100014271A (ko) | 2010-02-10 |
CN101595110A (zh) | 2009-12-02 |
MX2009005194A (es) | 2009-11-10 |
AU2006350748A1 (en) | 2008-05-22 |
WO2008060301A1 (en) | 2008-05-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CR10870A (es) | Derivados de purina 7-sustituidos para inmunosupresion | |
AR063141A1 (es) | Derivados de 2- ( benzimidazolil ) purina 8- sustituida para inmunosupresion | |
CL2011002956A1 (es) | Compuestos derivados de pirrolo[2,3-d]pirimidina, inhibidores de la quinasa janus (jak1); composicion farmaceutica; y uso para el tratamiento de una enfermedad autoinmune, cancer, trastorno mieloproliferativo, una enfermedad inflamatoria o rechazo de trasplante de organos. | |
ECSP109937A (es) | Pirimidil ciclopentanos como inhibidores de la proteína quinasa akt. | |
UY29149A1 (es) | Tiazolil-dihidro-indazoles | |
CR9840A (es) | Inhibidores de la pde y combinaciones de los mismos para el tratamiento de trastornos urologicos | |
CR11517A (es) | Derivados bis-(sulfonilamino) para uso en terapia | |
ECSP078013A (es) | Inhibidores heterocíclicos de mek y métodos de uso de ellos | |
ECSP11011284A (es) | Inhibidores de Poli (ADP-ribosa) Polimerasa (PARP) | |
CR10601A (es) | Ciclopenta (d) pirimidinas como inhibidores de la proteina cinasa akt | |
DOP2006000169A (es) | Inhibidores espiropiperidina de beta-secretasa para el tratamiento de la enfermedad de alzheimer | |
NO20075560L (no) | Purin og imidazopyridin derivater for immunsuppresjon | |
DOP2010000217A (es) | Compuestos de 3h-[1,2,3] triazolo[4,5-d]pirimidina, su uso como inhibidores de mtor quinasa y p13 y sus sintesis | |
ECSP099044A (es) | Compuestos de pirimido fusionados | |
GT200600035A (es) | Aminopiridinas como inhibidores de beta-secretasa | |
UY29826A1 (es) | Derivados de pirimidina, sales farmaceuticamente aceptables, esteres de los mismos hidrolisables in vivo, procesos de preparacion y aplicaciones | |
ECSP077268A (es) | Polimorfo ii de rapamicina y los usos de los mismos | |
CL2008001659A1 (es) | Compuestos derivados de quinoxalina como inhibidores de la actividad de cinasa de tirosina de las cinasas janus; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar una enfermedad inmunologica seleccionada a partir de rechazo de trasplante de organo, lupus, esclerosis multiple, entre otras enfermedades. | |
CL2012000707A1 (es) | Compuestos derivados de [5-(pirrolo[1,2-c][1.2.3]triazin-7-il)tetrahidrofuran-2-il]metanol; composición farmacéutica; y su uso para el tratamiento de la hepatitis c. | |
TW200631583A (en) | Substituted pteridines for the treatment of inflammatory diseases | |
CL2011001360A1 (es) | Compuestos derivados de imidazol[1,2-a]pirazin-8-amina, inhibidores de tirosina quinasa esplenica; composicion farmaceutica que comprende un compuesto; uso de los compuestos en la preparacion de medicamentos para el tratamiento de trastornos alergicos, enfermedades autoinmunes y enfermedades inflamatorias; y metodo in vitro. | |
CU20120059A7 (es) | Compuestos de pirrolo[2,3-d]pirimidina | |
CL2012000917A1 (es) | Compuestos derivados de pirazolo [3,4-d] pirimidina, inhibidores btk; y uso en el tratamiento del cancer, enfermedades autoinmune, mastocitosis,osteoporosis,entre otras. | |
WO2009024542A3 (en) | Purin derivatives for use in the treatment of fab-related diseases | |
RU2711869C3 (ru) | Имидазопирролопиразиновые производные, полезные для лечения заболеваний, вызванных аномальной активностью протеинкиназ Jak1, Jak3 или Syk |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA | Abandonment or withdrawal (granting procedure) |